Journal: Alzheimer's & Dementia
Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET
doi: 10.1002/alz.71147
Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
Article Snippet: Plasma samples were tested blinded in singlicate on the Lumipulse G1200 fully automated immunoassay platform using the commercially available Lumipulse G plasma p‐tau217 immunoreaction cartridge kits (Fujirebio Europe) according to manufacturer instructions.
Techniques: Clinical Proteomics, Derivative Assay